Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Novotech, Komipharm pair up on Panaphix trial
May 2020
SHARING OPTIONS:

SEOUL, KOREA—Novotech has been tapped to work with Komipharm International on a clinical trial evaluating Panaphix as a possible treatment for COVID-19. The drug is a cytokine storm inhibitor that prevents the overproduction of immune cells and cytokines, which in excess can result in severe inflammatory disease such as pneumonia. According to Dr. John Moller, CEO of Novotech, the company is well positioned to team up with Komipharm on this trial. Novotech has offices in 11 locations throughout the Asia Pacific region, and has conducted more than 200 projects in infectious diseases and vaccines, according to a company press release. In addition, over the course of the last year Novotech inked formal partnerships with several key Korean hospitals.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.